Эффективность применения трастузумаба в лечении диссеминированной HER2-положительной протоковой аденокарциномы подчелюстной слюнной железы (клинический случай)

Протоковая аденокарцинома слюнной железы является редкой злокачественной опухолью, характеризующeйся высокой частотой метастазирования и низкими показателями выживаемости. по данным иммуногистохимического исследования, у 40 % пациентов отмечается высокая экспрессия рецептора эпидермального фактора роста 2-го типа (HER2) (2–3+). при наличии отдаленных метастазов таргетная анти-HER2-терапия является единственным эффективным методом.

В статье представлен опыт успешного применения таргентной терапии при HER2-положительной потоковой аденокарциноме подчелюстной слюнной железы.

1. Jaehne M., Roeser K., Jaekel T. et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005;103(12):2526–33. DOI: 10.1002/cncr.21116

2. Luukkaa H., Klemi P., Leivo I. et al. Salivary gland cancer in Finland 1991–96: an evaluation of 237 cases. Acta Otolaryngol 2005;125(2):207–14. DOI: 10.1080/00016480510003174

3. Barnes L., Rao U., Krause J. et al. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 1994;78(1):64–73. DOI: 10.1016/0030-4220(94)90119-8

4. Laurie S.A., Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24(17):2673–8. DOI: 10.1200/JCO.2005.05.3025

5. Seifert G., Brocheriou C., Cardesa A., Eveson J.W. WHO international histological classification of tumours. Tentative Histological Classification of Salivary Gland Tumours.Pathol Res Pract 1990;186(5):555–81. DOI: 10.1016/S0344-0338(11)80220-7

6. Kleinsasser O., Klein H.J., Hubner G. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 1968;192(1):100–5. (In German).

7. Scholl S., Beuzeboc P., Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001;12(Suppl 1):S81–7. DOI: 10.1093/annonc/12.suppl_1.s81

8. Williams M.D., Roberts D., Blumenschein G.R. et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 2007;31(11):1645–52. DOI: 10.1097/PAS.0b013e3180caa099

9. Otsuka K., Imanishi Y., Habu N. et al. Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma. Nihon Jibiinkoka Gakkai Kaiho 2013;116(9):1024–32. DOI: 10.3950/jibiinkoka.116.1024

10. Masubuchi T., Tada Y., Maruya S. et al. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol 2015;20(1):35–44. DOI: 10.1007/s10147-014-0674-6

11. Skálová A., Stárek .I, Vanecek T. et al. Expression of HER2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2003;42(4):348–56. DOI: 10.1046/j.1365-2559.2003.01600.x

12. Marty M., Cognetti F., Maraninchi D. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as firstline treatment: the M77001 study group. J Clin Oncol 2005;23(19):4265–74. DOI: 10.1200/JCO.2005.04.173

13. Nabili V., Tan J.W., Bhuta S. et al. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007;29(10):907–12. DOI: 10.1002/hed.20614

14. Limaye S.A., Posner M.R., Krane J.F. et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist 2013;18(3):294–300. DOI: 10.1634/theoncologist.2012-0369

15. Brandwein-Gensler M.S., Skalova A., Nagao T. Salivary duct carcinoma. In: World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ed. by L. Barnes, J.W. Eveson, P. Reichart, D. Sidranksky. Lyon: IARC Press, 2005. Pp. 236–237.

16. Etges A., Pinto D.S., Kowalski L.P. et al. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 2003;56(12):914–8. DOI: 10.1136/jcp.56.12.914

17. Haddad R., Colevas A.D., Krane J.F. et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003;39(7):724–7. DOI: 10.1016/s1368-8375(03)00097-6

18. Press M.F., Pike M.C., Hung G. et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994;54(21):5675–82.

19. Glisson B., Colevas A.D., Haddad R. et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004;10(3):944–6. DOI: 10.1158/1078-0432.ccr-03-025

20. McKeage K., Perry C.M. Trastuzumab: a review of its usein the treatment of metastatic breast cancer overexpressing HER-2. Drugs 2002;62(1):209–43. DOI: 10.2165/00003495-200262010-00008

21. Bell R. Ongoing trials with trastuzumab in metastaticbreast cancer. Ann Oncol 2001;12(Suppl 1):S69–73. DOI: 10.1093/annonc/12.suppl_1.s69

22. Treish I., Schwartz R., Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm 2000;57(22):2063–79.

23. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001;37(Suppl 1):S18–24.

24. Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin Oncol 2000;27(5, Suppl 9):20–6.

25. Vogel C., Cobleigh M., Tripathy et al. Efficacy andsafety of trastuzumab as a single agent in first-linetreatment of HER-2overexpressing metastatic breastcancer. J Clin Oncol 2002;20(3):719–26. DOI: 10.1200/JCO.2002.20.3.719

26. Cortazar P., Zhang L., Untch M. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384(9938):164–72. DOI: 10.1016/S0140-6736(13)62422-8

27. Peddi P.F., Hurvitz S.A. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol 2013;9(3):319–26. DOI: 10.2217/fon.13.7

28. Lambert J.M., Chari R.J. Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014;57(16):6949–64. DOI: 10.1021/jm500766w

29. Welslau M., Diéras V., Sohn J.H. et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 2014;120(5):642–51. DOI: 10.1002/cncr.28465

30. Meric-Bernstam F., Makker V., Oaknin A. et al. Efficacy and safety of trastuzumab deruxtecan in patients with her2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47–58. DOI: 10.1200/JCO.23.02005

31. Takahashi S., Bando H., Kinoshita I. et al. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Jpn J Clin Oncol 2024;54(4):434–43. DOI: 10.1093/jjco/hyad181